Meeder Asset Management Inc Sage Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$27.52 - $37.99 $247 - $341	-9 Reduced 21.43%	33 $1,000
Q1 2022 May 10, 2022	BUY	$30.71 - $45.71 $1,289 - $1,919	42 New	42 $1,000
Q4 2021 Feb 11, 2022	SELL	$37.06 - $47.11 $296,294 - $376,644	-7,995 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$40.26 - $57.37 $269,540 - $384,092	6,695 Added 515.0%	7,995 $354,000
Q2 2021 Aug 09, 2021	BUY	$54.88 - $79.29 $66,679 - $96,337	1,215 Added 1429.41%	1,300 $74,000
Q1 2021 Apr 28, 2021	BUY	$70.65 - $96.76 $70 - $96	1 Added 1.19%	85 $6,000
Q3 2020 Nov 02, 2020	BUY	$41.13 - $62.45 $205 - $312	5 Added 6.33%	84 $5,000
Q2 2020 Aug 11, 2020	SELL	$25.95 - $43.15 $441 - $733	-17 Reduced 17.71%	79 $3,000
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $627 - $1,853	24 Added 33.33%	96 $3,000
Q4 2019 Feb 13, 2020	SELL	$60.18 - $154.77 $1,745 - $4,488	-29 Reduced 28.71%	72 $5,000
Q3 2019 Oct 17, 2019	SELL	$140.29 - $189.96 $140 - $189	-1 Reduced 0.98%	101 $14,000
Q2 2019 Aug 05, 2019	BUY	$157.85 - $183.09 $10,418 - $12,083	66 Added 183.33%	102 $19,000
Q1 2019 Apr 16, 2019	BUY	$89.33 - $163.65 $3,215 - $5,891	36 New	36 $6,000
Q3 2018 Nov 02, 2018	SELL	$138.11 - $169.04 $261,856 - $320,499	-1,896 Closed	0 $0
Q2 2018 Jul 24, 2018	BUY	$140.36 - $175.76 $211,522 - $264,870	1,507 Added 387.4%	1,896 $0
Q1 2018 May 03, 2018	BUY	$152.15 - $192.33 $31,951 - $40,389	210 Added 117.32%	389 $63,000
Q4 2017 Feb 02, 2018	BUY	$60.72 - $167.34 $9,897 - $27,276	163 Added 1018.75%	179 $29,000
Q3 2017 Oct 20, 2017	BUY	$61.4 - $88.52 $982 - $1,416	16	16 $1,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.